Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts

Key Points

• Maze Therapeutics, Inc. has received an average rating of "Buy" from analysts, with five analysts recommending a buy and two issuing strong buy ratings.
• The company's stock recently opened at $14.05, up 5.6%, and has a 1-year target price averaging $25.60 based on broker reports.
• Institutional investors have significantly increased their stakes in Maze Therapeutics, with notable new investments from firms like TRV GP IV LLC and Alphabet Inc..

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) has been assigned an average rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $25.60.

A number of equities research analysts have recently weighed in on MAZE shares. HC Wainwright started coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price for the company. Wedbush assumed coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective for the company. Finally, Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th.

Maze Therapeutics Stock Up 5.6%

MAZE stock opened at $14.05 on Wednesday. The firm's fifty day moving average is $14.00 and its 200 day moving average is $11.87. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. TRV GP IV LLC bought a new position in shares of Maze Therapeutics during the first quarter valued at about $66,874,000. Frazier Life Sciences Management L.P. increased its holdings in Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after purchasing an additional 438,274 shares during the period. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the 1st quarter valued at about $45,362,000. Matrix Capital Management Company LP bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $27,373,000. Finally, Alphabet Inc. purchased a new stake in Maze Therapeutics in the 1st quarter worth approximately $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.